Bristol Myers (NYSE: BMY) cell therapy chief exercises 8,192 shares, receives new units
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Bristol Myers Squibb President, Cell Therapy Org. Lynelle Hoch reported multiple equity compensation transactions in company stock. On March 10, 2026, she exercised derivative awards, including market share units and performance shares, converting them into a total of 8,192 shares of common stock.
The filing also shows new grants of 6,531 market share units and 9,796 performance share units, each tied to future performance measurement periods and vesting dates through 2029. A total of 1,391 common shares were withheld at $60.13 per share to cover tax obligations upon vesting. Following these transactions, Hoch directly holds 8,210 shares of Bristol Myers Squibb common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
8,192 shares exercised/converted
Mixed
14 txns
Insider
Hoch Lynelle
Role
President, Cell Therapy Org.
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Market Share Units | 838 | $0.00 | -- |
| Exercise | Market Share Units | 1,050 | $0.00 | -- |
| Exercise | Performance Shares | 6,304 | $0.00 | -- |
| Grant/Award | Market Share Units | 6,531 | $0.00 | -- |
| Grant/Award | Performance Shares | 9,796 | $0.00 | -- |
| Exercise | Common Stock, $0.10 par value | 838 | $0.00 | -- |
| Other | Common Stock, $0.10 par value | 94 | $0.00 | -- |
| Tax Withholding | Common Stock, $0.10 par value | 212 | $60.13 | $13K |
| Exercise | Common Stock, $0.10 par value | 1,050 | $0.00 | -- |
| Other | Common Stock, $0.10 par value | 113 | $0.00 | -- |
| Tax Withholding | Common Stock, $0.10 par value | 267 | $60.13 | $16K |
| Exercise | Common Stock, $0.10 par value | 6,304 | $0.00 | -- |
| Other | Common Stock, $0.10 par value | 3,095 | $0.00 | -- |
| Tax Withholding | Common Stock, $0.10 par value | 912 | $60.13 | $55K |
Holdings After Transaction:
Market Share Units — 0 shares (Direct);
Performance Shares — 0 shares (Direct);
Common Stock, $0.10 par value — 5,549 shares (Direct)
Footnotes (1)
- Represents vesting of one-quarter of market share units granted on March 10, 2022. Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Shares withheld for payment of taxes upon vesting of awards. Represents vesting of one-quarter of market share units granted on March 10, 2023. Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board. Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2026. Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.
FAQ
What did Bristol Myers (BMY) executive Lynelle Hoch report in this Form 4?
Lynelle Hoch reported a series of equity compensation events. These included exercises of market share units and performance shares into common stock, new grants of additional units, and share withholdings to pay taxes, all tied to Bristol Myers Squibb’s long-term incentive programs.
What new equity awards did Lynelle Hoch receive from Bristol Myers (BMY)?
Hoch received 6,531 market share units and 9,796 performance share units. These awards generally vest or distribute in future years, with terms tied to performance factors and Board certification, including distribution periods extending into the first quarter of 2029.
What is Lynelle Hoch’s Bristol Myers (BMY) stock ownership after these transactions?
After the reported transactions, Hoch directly holds 8,210 common shares. This post-transaction balance reflects the net effect of award exercises, new common shares acquired, and shares withheld to satisfy tax obligations associated with vesting equity compensation.